Chapter 18 of 25
What you will learn
- Understand lenvatinib–pembrolizumab and its monitoring needs.
- Recognize when hormonal or HER2-directed therapy may be appropriate.
- Separate approved indications from promising research.
Lenvatinib plus pembrolizumab
Lenvatinib blocks several signalling pathways, including those involved in tumour blood vessels. Pembrolizumab acts on the immune checkpoint PD-1. The combination is used in selected previously treated advanced endometrial cancer. The US label specifies pMMR or not MSI-H disease progressing after prior systemic treatment, when curative surgery or radiation is not appropriate. PD-L1 CPS is not the selection requirement.
KEYNOTE-775 compared the combination with physician-choice doxorubicin or paclitaxel in 827 previously treated patients. The updated pMMR analysis reported overall-survival HR 0.70 and PFS HR 0.60. These are comparative trial results, not cure probabilities. The study does not establish the best sequence after today's first-line chemo-immunotherapy, so prior checkpoint exposure is an important limitation.
High blood pressure, diarrhoea, fatigue, appetite or weight loss, thyroid changes, protein in urine and immune effects require active monitoring. Serious bleeding, vascular events, fistula or organ injury are less common but important risks. Dose interruptions and reductions are common clinical tools. An oral medicine is not necessarily a mild treatment; home blood-pressure monitoring and a clear symptom plan may be needed.
Hormonal treatment
Hormonal therapy may suit selected low-grade, ER/PR-positive, slowly progressing advanced or recurrent cancers, especially when symptoms and disease burden allow a less intensive approach. Options include progestins and aromatase inhibitors; other combinations are selected by specialists or studied in trials. Receptor positivity increases biological plausibility but does not guarantee response.
Progestins can cause appetite and weight changes, fluid retention and thrombosis risk. Aromatase inhibitors can cause joint symptoms and bone loss. Menopausal status, medicines and bone health affect choices. Hormonal therapy is not a universal replacement for curative surgery, and it may be unsuitable for rapidly progressive symptomatic disease needing a faster response.
HER2-directed treatment
A randomized phase II study in selected HER2-positive advanced or recurrent uterine serous carcinoma supported adding trastuzumab to carboplatin/paclitaxel. The study was small and does not establish benefit for every endometrial histology. Appropriate HER2 testing and heart-function monitoring are relevant.
The US tumour-agnostic accelerated approval for trastuzumab deruxtecan covers selected previously treated unresectable or metastatic HER2 IHC 3+ solid tumours with no satisfactory alternatives. This is not an automatic indication for every HER2 2+ result or for first-line use. Serious lung inflammation can occur; new cough or breathlessness requires prompt contact. Local approvals may differ.
Emerging approaches and trial questions
| Approach | How to interpret it |
|---|---|
| Molecularly selected established therapy | Confirm the exact biomarker and disease-setting eligibility |
| Broader tumour sequencing | May reveal an approved tumour-agnostic option or trial, but many findings are not actionable |
| PARP or CDK4/6 combinations | Some region-specific options and ongoing research; avoid assuming class-wide approval |
| RAINBO postoperative strategies | A research programme, not a proven menu for all four groups |
The European durvalumab–olaparib maintenance pathway in pMMR disease is a specific regional approval, not evidence that any PARP inhibitor can be added to any immunotherapy regimen. Ask whether a recommendation is guideline-supported, locally approved, off-label or investigational, and what evidence applies after your previous treatments.
The RAINBO programme includes studies of adding olaparib after chemoradiation in p53-abnormal disease, durvalumab with radiation in MMRd disease, hormonal approaches in NSMP and treatment reduction in POLE-mutated disease. These are molecularly directed research questions; no mature efficacy results were identified in this evidence check. Trial protocols and recruitment should be checked directly.
Questions and take-home messages
Ask what target is present, what outcome the trial measured and how toxicity will be monitored. Discuss costs and travel as part of treatment feasibility. Supplements marketed as “targeted” or “hormone balancing” are not substitutes and can interact with cancer medicines.
Related chapters
- Treatment of Early-Stage Endometrial Cancer
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- KEYNOTE-775 updated efficacy and safety, JCO 2023
- DailyMed: Lenvima prescribing information
- Fader et al. Trastuzumab in HER2-positive uterine serous carcinoma, 2020
- FDA HER2 IHC 3+ solid-tumour accelerated approval, April 2024
- EMA: Imfinzi, current European indications
- RAINBO molecularly directed research programme protocol, 2023
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy